Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Formulations of Eltrekibart in Healthy Participants'. The following are the other relevant details related to the trial:
Therapeutic Area: Immunology
Trial Centre(s):
Lilly Centre for Pharmacology
Trial Status: NA
Principal Investigator(s):
Dr Greg Li
Published by HT Digital Content Services with permission from Health Daily Digest....